Nuwellis Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.
Last trade$4.32
Day change-$0.16 (-3.57%)
Day range$4.08 – $4.57
Volume12,871
Market cap$2M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$2.42M
Price / earnings
—
Price / book
0.25×
Price / sales
0.27×
EV / sales
-0.65×
EV / EBITDA
0.49×
Profitability
Earnings per share
-$25.43
Return on assets
-102.31%
Return on equity
-139.57%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
3.99×
Quick ratio
3.4×
Cash ratio
2.77×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$12.31M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for NUWE, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$2.21M
$1.97M
$2.4M
$2.42M
$2.22M
$1.73M
$1.9M
$2.32M
Cost of revenue
$674K
$471K
$719K
$770K
$772K
$767K
$837K
$967K
Gross profit
$1.54M
$1.5M
$1.68M
$1.65M
$1.45M
$958K
$1.07M
$1.36M
Selling, general and administrative
$3.01M
$3.73M
$4.52M
$3.21M
$3.54M
$3.19M
$3.58M
$2.91M
Research and development
$584K
$942K
$1.73M
$884K
$603K
$675K
$550K
$831K
Total operating expenses
$3.59M
$4.67M
$6.25M
$4.1M
$4.14M
$3.86M
$4.13M
$3.74M
Operating income
-$2.05M
-$3.17M
-$4.57M
-$2.44M
-$2.7M
-$2.91M
-$3.06M
-$2.39M
Interest expense
-$61K
-$6.08M
$0
$0
$0
-$10.55M
$0
$0
Income before taxes
-$1.97M
-$4.83M
-$4.54M
-$2.42M
$468K
-$12.55M
-$3.01M
-$1.47M
Income taxes
$0
$0
$0
$0
$0
$4K
$1K
$1K
Net income
-$1.97M
-$4.83M
-$4.54M
-$2.42M
$468K
-$12.55M
-$3.01M
-$1.47M
Net income attributable to common shareholders
-$1.97M
-$4.83M
-$4.54M
-$2.42M
$468K
-$12.55M
-$3.01M
-$1.47M
EBITDA
-$2.02M
-$3.13M
-$4.53M
-$2.41M
-$2.65M
-$2.86M
-$2.99M
-$2.3M
Basic earnings per share
-$5.81
-$239.76
-$689.85
-$472.44
$176.87
-$19,207.71
-$9,112.95
-$6,244.56
Diluted earnings per share
-$5.81
-$239.76
-$689.85
-$472.44
$176.87
-$19,207.71
-$9,112.95
-$6,244.56
Recent news
Company coverage with links to the original publishers.
Nuwellis announced publication of the ULTRA-Peds Registry study in Pediatric Nephrology, evaluating 91 pediatric patients across seven children's hospitals using the Aquadex SmartFlow System. The study demonstrated 87% patient survival rates and 86.5% procedure completion without interruption, with 62% of patients weighing less than 10 kg. These findings support the company's proposed FDA label expansion for Aquadex from patients weighing 20 kg and above to those weighing 5 kg and above, following a successful pre-submission meeting with the FDA earlier in 2026.
Nuwellis announced a co-promotion and distribution agreement with Atrility Medical for the AtriAmp device, an FDA-cleared technology for temporary epicardial pacing. The deal includes an initial six-month pilot across nine Western and five Southeastern states, with a pathway to exclusive U.S. distribution upon successful completion. This strategic partnership allows Nuwellis to expand its pediatric and critical care portfolio without significant additional infrastructure investment.
Nuwellis (NUWE) announced a $3.4 million registered direct offering of 1,310,890 shares at $2.59 per share, along with $3.1 million in warrant exercise proceeds from its June 2026 public offering. The company will also issue concurrent warrants to investors with a five-year term. The offering is expected to close on August 3, 2026.
Nuwellis, Inc. (Nasdaq: NUWE) marks five years of supporting the Pediatric Cardiac Critical Care Consortium (PC4) annual conference, collaborating with leading pediatric cardiac institutions to advance fluid management education and awareness. The company's Aquadex SmartFlow system is utilized across major pediatric cardiac centers for managing fluid overload in critically ill children. Incoming CEO Mike McCormick emphasized the company's commitment to pediatric care advancement and fluid management strategies in cardiac ICUs.
Nuwellis (NASDAQ: NUWE), a medical technology company focused on cardiorenal conditions, announced the successful closing of a $6.0 million registered public offering. The offering included 1.9 million shares of common stock and pre-funded warrants, with accompanying Series C and D warrants. The public offering price was $0.30 per share with accompanying warrants.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.